AI-Powered Formulation Intelligence

From Empirical Formulation
to Intelligence-Driven
Biologics Formulation

FormulytiX is a focused formulation intelligence platform for biologics — combining RAG architecture, in silico stability modeling, and expert decision support. All outputs require scientific review and are not intended as validated regulatory submissions. Currently in pre-development (v0.1) — capabilities reflect MVP scope and planned roadmap.

Explore Modules → How It Works
LEXIS · Excipient Intelligence
mAb Formulation Analysis
mAb SC Aggregation Risk: Low
Representative Output · Conceptual
High
Stability Confidence
ICH Q5C
Guideline Framework
RAG
Cited Sources
Early
Decision Support
🔬
RAG-Based Auditability
🇨🇭
Swiss Cloud Hosting
📋
CTD/IMPD Workflow Support
🛡️
GxP-Aware Architecture
🔗
Native BioXion Bridge
Market Convergence

Why Now Is the Moment
for Formulation Intelligence

Four converging forces create an unprecedented market window for a focused, regulatory-aware formulation intelligence platform.

01
RAG Architecture Maturity
Retrieval-Augmented Generation now delivers traceable, citable outputs — a prerequisite for GxP-regulated pharmaceutical environments where black-box AI cannot be tolerated.
02
Exploding Knowledge Base
Rapid growth of publicly available peer-reviewed literature, patent databases, EPARs, and FDA product review documents creates the infrastructure for scientifically meaningful AI depth.
03
Rising Biologics Complexity
Pipelines shift toward high-concentration SC injectables, bispecifics, and novel modalities — empirical formulation approaches are reaching their practical limits.
04
Phase 3 Attrition Pressure
Industry-wide pressure to reduce late-stage clinical failures driven by stability and manufacturability issues that could have been identified earlier with better decision support.
Six Specialized Modules

Focused Biologics
Formulation Intelligence

Operate formulation-focused modules independently or as an integrated intelligence layer supporting early-to-late development decisions.

Phase 1 · MVP
Module A
LEXIS
Literature & Excipient Intelligence
Automated mining of scientific journals, patents, regulatory guidelines, and excipient databases via RAG. Every output is fully citable and traceable for regulatory review.
Sequence-to-formulation guidance for mAbs & proteins
Excipient compatibility with confidence-weighted rationale
FDA Purple Book / EMA EPAR regulatory precedent mining
Phase 2 · Planned
Module B
ROUTEX
Delivery Route & Administration Optimization
Scenario-based modeling of delivery route feasibility. Supports early go/no-go decisions before costly clinical studies — essential for patient-centric SC injectable design.
Viscosity modeling & injectability assessment
Auto-injector platform compatibility mapping (Ypsomed, SHL, BD)
High-concentration protein concentration optimization
Phase 1 · MVP
Module C
STABILIS
Stability Simulation & Risk Modeling
In silico analysis of degradation pathways and long-term stability risk. Operates as a digital decision-support layer alongside ICH stability studies.
ICH Q1A & Q5C study design framework generation
Arrhenius kinetics long-term stability projection
OOS/OOT early signal detection
Phase 2 · Planned
Module D
DEVIX
Developability Assessment & Candidate Scoring
Structured assessment of early-stage candidates based on manufacturability and formulatability profile — before significant R&D investment is committed.
Comparative candidate assessment (3–5 leads ranked)
APR, hydrophobicity patch & disulfide stability flagging
CDMO equipment compatibility risk profile
Phase 2 · Planned
Module E
COMPEX
Competitive & Patent Intelligence
Global patent monitoring, approved product formulation analysis, and competitor pipeline tracking — supporting IP-aware formulation decisions from early development.
Freedom-to-operate risk assessment with claim scope analysis
Formulation whitespace mapping
Biosimilar reference product intelligence
Phase 2 · Planned
Module F
REGIX
Regulatory Drafting & Intelligence Assistant
AI-assisted support for CTD narrative drafting and cross-document consistency review. Designed for integration with BioXion for connected formulation-to-CMC workflows.
CTD Section 3.2.P structured drafting support (EMA / FDA / Swissmedic)
Dossier cross-reference consistency checker
ICH / EMA / FDA guideline currency monitoring
Cross-Cutting Capability

The Analogous
Molecule Engine

A horizontal AI capability operating across all modules — shared molecular intelligence that amplifies every individual module's value. Active from Phase 1.

Upon submission of a new molecule, the AME identifies the most structurally and therapeutically analogous molecules, retrieves their formulation data, stability profiles, and regulatory intelligence, and pre-populates this as contextual input across all active modules.

⚡ Designed to significantly reduce early-stage formulation intelligence gathering time — evidence-anchored from day one.
LEXIS
REGIX
STABILIS
DEVIX
COMPEX
ROUTEX
AME
Core
Technical Foundation

Designed for Regulatory-Aligned
Scientific Environments

🧠
RAG Architecture
All outputs are designed to be grounded in verifiable, citable scientific literature. Unlike black-box AI, RAG-based responses are intended to be fully traceable to source documents — a key requirement for GxP-regulated environments.
🔬
Domain-Specific LLMs
Pharmaceutical and biotechnology-oriented models with task-specific components designed to support stability risk estimation, developability profiling, and molecular property assessment.
🏗️
Modular API-First
Each module is designed to expose a documented API to support integration with existing LIMS, ELN platforms (Dotmatics, LabWare, IDBS), and clinical data management systems — subject to Phase 2 roadmap.
🇨🇭
Swiss Data Sovereignty
Private cloud infrastructure on Azure Switzerland North. Proprietary molecular sequences and formulation data are designed to remain within the client's secure cloud tenancy.
⚖️
Dual AI Layers
Retrieval layer for evidence-based guidance, generative layer for structured outputs. Both are designed to be independently auditable — all outputs intended as expert decision support, not autonomous conclusions.
🔗
BioXion Integration
Structured outputs designed to flow directly into BioXion's regulatory dossier module (CTD/IMPD), reducing manual re-entry and cross-document inconsistency risk.
Target Audience

Built for Three
Critical Segments

01
Biotech & Virtual Pharma
Limited CMC Capacity
Organizations with promising biologics candidates but limited internal CMC expertise. FormulytiX is designed to deliver AI-assisted formulation guidance, intended to support early development stages where formulation decisions carry the highest downstream impact.
02
CDMOs
Multi-Project Pipeline Management
Organizations managing formulation development across multiple client biologics programs simultaneously. FormulytiX is designed to deliver scalable intelligence intended to support throughput and traceability — a meaningful differentiator where scientific rigor and auditability are valued.
03
Mid-Size Biopharma
AI-Augmented Internal Teams
Organizations with internal CMC teams seeking to reduce Phase 3 stability-related failures, accelerate regulatory submission timelines, and systematize formulation decision-making across their biologics portfolio through AI-supported decision insights.
HTS Digital Thread

The Full Lifecycle
Intelligence Platform

FormulytiX
Formulation Intelligence
⟶
BioXion
CMC & Regulatory Execution
CTD 3.2.P Draft
⟶
IMPD Dossier
⟶
MAA Submission

Designed to support CTD/IMPD content development workflows — structured outputs aligned with dossier preparation needs.

🔁
REGIX → BioXion Bridge
REGIX module outputs are structured to flow directly into BioXion's CTD/IMPD module, significantly reducing manual transcription effort and cross-document inconsistency.
🔄
Cross-Platform Client Acquisition
Every FormulytiX client is a natural BioXion prospect and vice versa — creating cross-platform acquisition efficiency and durable recurring revenue through integrated data models.
🏢
Distinct, Complementary Roles
FormulytiX focuses exclusively on formulation intelligence, while BioXion provides broader CMC program intelligence — both designed to operate together as a connected layer from early-stage formulation decisions through CMC program management.
Development Roadmap

Phased Deployment
for Maximum Impact

Phase 1 · Planned (MVP Scope)
Biologics Core MVP
  • Monoclonal antibodies (mAbs) — primary focus
  • Recombinant proteins (enzymes, Fc-fusion constructs)
  • LEXIS — Literature & Excipient Intelligence
  • STABILIS — Stability Simulation & Risk Modeling
  • Analogous Molecule Engine (AME) core
  • Pilot with 2–3 CDMO or biotech partners
  • Real-world case studies for commercial launch
Phase 2 · Roadmap 2026
Platform Expansion & Integration
  • BsAbs, ADCs, viral vectors, mRNA/LNP
  • Oligonucleotides, peptides, selected small molecules
  • ROUTEX — Delivery Route Optimization
  • DEVIX — Developability Assessment
  • COMPEX — Competitive & Patent Intelligence
  • REGIX — Regulatory Drafting Assistant
  • Full BioXion integration & commercial go-to-market

Ready to Transform
Your Formulation Process?

Join the pilot cohort of CDMOs and biotech partners shaping the future of AI-driven biologics formulation intelligence.

Express Your Interest → Learn More at HTS

Important Notice: FormulytiX is designed as an AI-assisted decision support platform currently in pre-development phase. All outputs require expert scientific evaluation and are not intended for direct regulatory submission. Platform capabilities described represent the intended MVP scope and planned roadmap — not a deployed production system.